Adp53 + docetaxel

Adp53 + docetaxel is a combination therapy that has been investigated for treating various types of cancer, particularly non-small-cell lung cancer (NSCLC) and advanced solid tumors. This combination pairs an adenoviral vector delivering the wild-type p53 gene (Adp53) with docetaxel, a chemotherapeutic agent. ## Description Adp53 + docetaxel combines two distinct therapeutic approaches: 1. **Adp53 (Adenoviral p53)**: A replication-deficient adenovirus containing human p53 cDNA designed to restore p53 function in cancer cells. The mechanism of action involves the adenoviral vector infecting cancer cells and expressing the wild-type p53 gene, which can induce apoptosis (programmed cell death) in cancer cells with mutated or inactivated p53[1][5]. 2. **Docetaxel**: A taxane-based chemotherapeutic agent that works by disrupting microtubule function, which is essential for cell division, thereby preventing cancer cells from dividing properly. The combination therapy aims to enhance anti-tumor efficacy through complementary mechanisms - restoring p53 tumor suppressor function while simultaneously attacking cancer cells with conventional chemotherapy.

Other names

DOCp53DOCp-53DOCp 53